Cambrex has posted a positive set of Q2 results, recording an operating income of $9m (€6.3m), but warned that the second half of the year is likely to be down on the corresponding six months of last year.
Cambrex posted a 5 per cent hike in revenues in the second quarter, helped by its shift into contract controlled substance manufacture, although without favourable currency effects sales would have slipped back 2.6 per cent.
Cambrex Corp, the US-based manufacturer of small-molecule active
pharmaceutical ingredients (APIs) and advanced intermediates for
the drug industry, has announced that one of its customers is
recalling a product for which Cambrex...
Life sciences firm Cambrex has reported a $140.3m (€116.7m) loss in
Q4 as opposed to a profit of $4.9m in Q4 last year, hit by lower
long-term profitability projections for its Biopharma unit, as
biotech companies seem to lose their...
Cambrex has recorded a gain in the third quarter of this year, with
growth in its Bioproducts and Human Health segments. The company's
troublesome BioPharma division continues to underperform,
indicative of a market for outsourced...